Dublin, Ireland--(Marketwire - November 19, 2007) -
AGI Therapeutics to present at 19th Annual Piper Jaffray Health Care Conference
in New York
-- 1.30 p.m., Tuesday 27 November, 2007 --
Dublin, Ireland, November 19th 2007 - AGI Therapeutics plc ("AGI" or the
"Company") (AIM, IEX: AGI), the speciality pharmaceutical company focused on
gastrointestinal drug products, today announces that the Company's Chief
Executive Officer, Dr. John Devane, will make a presentation at the 19th Annual
Piper Jaffray Health Care Conference in New York.
Dr. Devane will deliver his presentation on Tuesday 27 November 2007 at 1.30
p.m. EDT (5.30 p.m. UKT). Investors may access an audio webcast of the
presentation at
http://www.piperjaffray.com/conferences.
A copy of the presentation will be available after the event on the AGI website
at
www.agitherapeutics.com under the "Investors: Publications" tab.
For further information please contact:
AGI Therapeutics plc Tel: +353 1 449 3254
David Kelly, Chief Financial Officer
Financial Dynamics - UK Tel: +44 (0) 20 7831 3113
Deborah Scott/Lara Mott
Piper Jaffray Limited Tel: +44 (0) 20 3142 8700
Neil Mackison
Will Carnwath
About AGI Therapeutics plc
AGI (the company) is a specialty pharmaceutical company which is focused on the
development and commercialisation of differentiated drug products for
gastrointestinal (GI) diseases and disorders. AGI's common shares are listed on
the Alternative Investment Market of the London Stock Exchange (AIM) and on the
Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.
The company has a portfolio of product candidates derived from its Known
Molecular Entity (KME) approach to drug re-profiling and development. RezularTM,
AGI's lead product, is in Phase III clinical trials for the treatment of IBS-D.
About RezularTM (AGI-003)
Rezular (AGI-003) is an orally administered triple-action intestinal regulator,
a first-in-class mechanism for the treatment of IBS-D. Rezular contains
arverapamil, a single enantiomer moiety of the racemic drug verapamil. Unlike
the currently available commercial forms of racemic verapamil (a mixture of two
enantiomers), Rezular shows a dominant activity in treating the symptoms of
IBS-D without the traditional cardiovascular actions of the racemic drug. The
efficacy and safety of Rezular in IBS patients has already been established in a
Phase II trial, the preliminary results of which were reported by the Company in
2006.
About IBS-D
Irritable bowel syndrome (IBS) is a functional disorder that comprises a cluster
of gastrointestinal symptoms which are likely to be life long and which affect
between 10% and 20% of the population in developed markets. IBS remains the
most common diagnosis made by gastroenterologists and can lead to a substantial
reduction in patients' quality of life, accompanied by considerable
socio-economic and psychological consequences. Altered intestinal motility is a
major component of IBS and patients are diagnosed and sub-typed according to
their predominant symptom of bowel disturbance. Diarrhoea-predominant irritable
bowel syndrome (IBS-D) is estimated to occur in one-third of all IBS patients.
IBS-D represents a significant unmet medical need as there are currently few
safe and effective therapeutic options available to these patients.
For further information please see
www.agitherapeutics.com
This information is provided by RNS
The company news service from the London Stock Exchange